Fintech News

‹ Latest Events

NVAX
NASDAQ

Novavax, Inc.

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady - NVAX

Published October 16, 2026

$11.26
-12.17%
Event

Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady - NVAX

Read full article on 247wallst.com →
About Novavax, Inc.

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Stock Price
$11.26
Price Change
-1.56%
Exchange Mix — Recent NVAX Events

NASDAQ

100%

NYSE

0%

AMEX

0%

OTC

0%